Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy

Core Evidence

Volumn 10, Issue , 2014, Pages

  Graff, Julie N ^a   Chamberlain, Erin D ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Economic analysis; Efficacy; Prostate cancer; Sipuleucel T

Indexed keywords

ABIRATERONE; ANALGESIC AGENT; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; SIPULEUCEL T;

ANTIGEN PRESENTING CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; EOSINOPHIL COUNT; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOLOGICAL PARAMETERS; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84946691816     PISSN: 15551741     EISSN: 1555175X     Source Type: Journal    
DOI: 10.2147/CE.S54712     Document Type: Review

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650-1656.
3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
4. Ryan C, Smith M, Fizazi K, Miller K. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. European Society of Medical Oncology Annual Meeting. 2014:Abstract 753O. Available from: file:///C:/Users/susan/Downloads/Genitourinary-tumours-prostate-1.pdffile:///C:/Users/susan/Downloads/Genitourinary-tumours-prostate-1.pdf. Accessed November 15, 2014.
5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433.
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
9. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
11. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3): 213-223.
12. Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012;188(4):1164-1169.
13. Dendreon Corporation. Package insert. Provenge® (sipuleucel-T). Seattle, WA, USA: Dendreon Corporation; 2010.
14. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117(3):471-477.
15. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10(6):425-434.
16. Jubinsky PT, Laurie AS, Nathan DG, Yetz-Aldepe J, Sieff CA. Expression and function of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit. Blood. 1994;84(12):4174-4185.
17. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother. 2008;42(1):91-98.
18. Bilusic M, Heery C, Madan RA. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine. 2011;29(38):6485-6497.
19. Gomella LG, Gelpi-Hammerschmidt F, Kundavram C. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. Can J Urol. 2014;21(2 Suppl 1):48-56.
20. Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11): pii dju268.
21. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res. 2005;11(6):2416-2426.
22. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-3094.
23. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-3679.
24. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
25. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104(4):273-279.
26. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763-2767.
27. Higano C, Saad F, Somer B, et al. A phase 3 trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Presented at the 2009 Genitourinary Cancers Symposium. Proc Am Soc Clin Oncol. 2009:Abstr LBA150.
28. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104(14):1107-1109.
29. Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis. 2014;17(3):259-264.
30. [No authors listed]. Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED. Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):11.
31. [No authors listed]. Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts). Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):8.
32. McNeel DG, Gardner TA, Higano CS, et al. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014;2(10):988-999.
33. Drake C, Fan L, Thakurta D, Stewart F, Kantoff P, Small E. Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. J Clin Oncol. 2014;32 Suppl 4:Abstr 88.
34. GuhaThakura D, Fan L, Vu T, Sheikh NA, Trager JB. Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome. J Immounother Cancer. 2013;1 Suppl 1:P101.
35. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011;17(13):4558-4567.
36. Beer TM, Schellhammer PF, Corman JM, et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology. 2013;82(2):410-415.
37. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196.
38. Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet. 1976;1(7965):899-900.
39. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
40. Holko P, Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2014;14(1):63-73.
41. Small EJ, Lance RS, Redfem CH, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31 Suppl:Abstr 5047.
42. Quinn DI, Petrylak DP, Pieczonka CM, et al. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32 Suppl:Abstr 16071.
43. Mouraviev V, Mariados N, Albala D, Concepcion RS, et al. The rationale for optimal combination therapy with sipuleucel-T for patients with castration-resistant prostate cancer. Rev Urol. 2014;16(3):122-130.